Quince Therapeutics, Inc.
QNCX
$30.32
$0.822.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 289.64% | 17.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 98.77% | -31.56% | |||
| Operating Income | -98.77% | 31.56% | |||
| Income Before Tax | -346.67% | 184.20% | |||
| Income Tax Expenses | 101.40% | -269.71% | |||
| Earnings from Continuing Operations | -310.20% | 191.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -310.20% | 191.01% | |||
| EBIT | -98.77% | 31.56% | |||
| EBITDA | -99.04% | 31.62% | |||
| EPS Basic | -115.72% | 155.25% | |||
| Normalized Basic EPS | -106.05% | 140.69% | |||
| EPS Diluted | -115.72% | 155.25% | |||
| Normalized Diluted EPS | -106.05% | 140.69% | |||
| Average Basic Shares Outstanding | 1,237.29% | 64.73% | |||
| Average Diluted Shares Outstanding | 1,237.29% | 64.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||